Non-small cell lung cancer (NSCLC)
Conditions
Brief summary
Pathological Complete Response (pCR)
Detailed description
1. Overall survival, 2.Progression-free survival, 3. Major pathological response rate, 4. Downstaging, 5. Portion of delayed/canceled surgeries, length of hospital stays, surgical approach, incidence of AE/SAE related to surgery, 6. Mortality at 90 days after surgery, 7. Safety and tolerability: Adverse events graded according to CTCAE v5.0, 8. Biomarker endpoints, 9. To determine the association between MPR and histology, 10. To determine the association of the histology with the progression free survival at 18 months
Interventions
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Fundacion GECP
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response (pCR) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Overall survival, 2.Progression-free survival, 3. Major pathological response rate, 4. Downstaging, 5. Portion of delayed/canceled surgeries, length of hospital stays, surgical approach, incidence of AE/SAE related to surgery, 6. Mortality at 90 days after surgery, 7. Safety and tolerability: Adverse events graded according to CTCAE v5.0, 8. Biomarker endpoints, 9. To determine the association between MPR and histology, 10. To determine the association of the histology with the progression free survival at 18 months | — |
Countries
Spain
Outcome results
None listed